Researchers are testing the effectiveness of Metformin to help improve daily living for individuals with Fragile X syndrome.
The trial further assesses Metformin’s safety, as well as the benefits of the drug, which has been shown to improve the symptoms and difficulties individuals with FXS experience, including: delayed language/cognition, excessive eating, obesity, hypogonadism, and delayed puberty.
Who can participate?
Individuals aged 6–25 who have been diagnosed with FXS (and who fit the inclusion/exclusion criteria).
What will happen in the study?
Commit to a four-month study which includes three clinic visits, and five phone calls while taking Metformin orally. Complete various tasks, questionnaires, and examinations by a physician/research team, as well as have blood drawn, as well as urine and stool samples taken.
Will you/your child be paid to complete this survey?
Travel expenses will be reimbursed.
Study doctors and locations
Please fill out the form below to send your contact information to the study coordinators.
Dr. Francois Bolduc, Principal Investigator
University of Alberta/Stollery Children’s Hospital
Edmonton, Alberta, Canada
Dr. Sébastien Jacquemont, Principal Investigator
CHU Ste. Justine
Montreal, Quebec, Canada
Study Coordinators: Maryse Thibeault or Sophie Morin
Our Most Recent Opportunities
The Research in Neurodevelopmental Disabilities Lab at the Waisman Center at the University of Wisconsin-Madison is looking for parents of male or female children 6 to 17 years old with Fragile X syndrome for an online survey.
RTI International and the University of North Carolina at Chapel Hill are conducting an early intervention study to learn about the best ways to support early development in infants identified with the full mutation of Fragile X. Babies 0–9 months old with the full mutation, and their caregivers, may be eligible to participate.
Doctors at Rush University are researching cognition, balance, and walking patterns in people who carry a premutation in the Fragile X (FMR1) gene.
The University of South Carolina is conducting a research study focusing on the range of language, social, and cognitive features that may be associated with variations on the FMR1 gene. Women age 35-75 who are carriers of the Fragile X premutation may be eligible to participate.